Erenumab in Chronic Migraine Patients Who Previously Failed Five First-Line Oral Prophylactics and OnabotulinumtoxinA: A Dual-Center Retrospective Observational Study

Background: German authorities reimburse migraine prevention with erenumab only in patients who previously did not have therapeutic success with at least five oral prophylactics or have contraindications to such. In this real-world analysis, we assessed treatment response to erenumab in patients wit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Neurol
Autors principals: Raffaelli, Bianca, Kalantzis, Rea, Mecklenburg, Jasper, Overeem, Lucas Hendrik, Neeb, Lars, Gendolla, Astrid, Reuter, Uwe
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2020
Matèries:
Neurology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7270347/
https://ncbi.nlm.nih.gov/pubmed/32547474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fneur.2020.00417
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars